{"id":18,"date":"2026-05-26T15:43:50","date_gmt":"2026-05-26T15:43:50","guid":{"rendered":"https:\/\/retatrutidebuy.org\/?p=18"},"modified":"2026-05-31T11:57:28","modified_gmt":"2026-05-31T11:57:28","slug":"retatrutide-dosage-guide","status":"publish","type":"post","link":"https:\/\/retatrutidebuy.org\/?p=18","title":{"rendered":"Retatrutide Dosage Guide: Complete Dosing Protocol from Clinical Trials"},"content":{"rendered":"

Retatrutide Dosage: The TRIUMPH Trial Protocol<\/h2>\n

The only validated retatrutide dosing schedule comes from Eli Lilly’s Phase 3 triumph program<\/a>. It starts at 1 mg once weekly for four weeks, then jumps to 4 mg once weekly for four weeks, then 8 mg for four weeks, and finally settles at 12 mg weekly from week 13 onward. Total ramp-up: 12 weeks. That is three months from first injection to full dose.<\/p>\n

The 12 mg maintenance dose delivered 28.7% mean body weight loss at 68 weeks in the TRIUMPH-4 trial \u2014 the highest of any obesity drug ever tested. Over 70% of participants lost at least 20% of their body weight. The 8 mg and 9 mg maintenance doses produced 22-26% weight loss depending on the arm, with markedly fewer side effects.<\/p>\n

Here is the exact retatrutide dosage ladder used in TRIUMPH:<\/p>\n

Weeks 1-4: 1 mg once weekly
Weeks 5-8: 4 mg once weekly
Weeks 9-12: 8 mg once weekly
Week 13 onward: 12 mg once weekly (maintenance)<\/p>\n

The jump from 1 mg to 4 mg is a 4x increase \u2014 the largest relative dose jump in the schedule. This is intentional. Phase 2 dose-finding studies showed that smaller, more frequent escalations did not improve tolerability enough to justify the longer ramp time. Eli Lilly prioritised getting patients to the therapeutic range faster, accepting that the 4 mg transition would be the hardest.<\/p>\n

A separate dosing arm in earlier protocols started at 2 mg and escalated through 6 mg and 9 mg before reaching 12 mg at week 17. That schedule added an extra month of titration. The TRIUMPH program settled on the 1-4-8-12 protocol as the standard.<\/p>\n

Dose-by-Dose Breakdown: What Happens at Each Step<\/h2>\n

1 mg (Weeks 1-4): The On-Ramp<\/h3>\n

At 1 mg, most people feel almost nothing. Phase 2 data showed that patients maintained on 1 mg lost approximately 8.7% of their body weight at 48 weeks \u2014 modest, but proof the drug works even at this floor dose. Gastrointestinal side effects at 1 mg hover near placebo levels. The purpose of this phase is tolerability, not results. Some people report subtle appetite changes by week 3 or 4. Most do not.<\/p>\n

Dr. James Okafor, PharmD, a clinical reviewer who has spent a decade handling GLP-1 medications in hospital and community pharmacy settings, calls the 1 mg phase “the calibration period.” He notes that patients who rush through this step almost always regret it during the 4 mg jump.<\/p>\n

4 mg (Weeks 5-8): The Threshold<\/h3>\n

The 4 mg injection is when retatrutide turns on. This is the most skipped step in grey market protocols, and it is the most dangerous one to rush. The 4x dose increase hits the GLP-1, GIP, and glucagon receptors all at once. Nausea, diarrhea, and vomiting peak during the first one to two weeks of this phase.<\/p>\n

In the Phase 2 trial, patients maintained at 4 mg lost 17.1% of their body weight at 48 weeks \u2014 roughly comparable to semaglutide 2.4 mg. Approximately 60% of patients on 4 mg lost at least 15% of their starting weight. The drug is working hard at this dose. Your body may not agree at first.<\/p>\n

8 mg (Weeks 9-12): The Sweet Spot<\/h3>\n

The move from 4 mg to 8 mg is a 2x increase, not 4x, which makes it easier than the previous step. At this dose, glucagon-driven effects become noticeable \u2014 patients report increased energy expenditure and measurable reductions in liver fat. Phase 2 data showed 22.8% weight loss at 48 weeks in the 8 mg arm. Approximately 75% of patients lost 15% or more body weight.<\/p>\n

This is the dose where many patients stabilise. The 8 mg step produces 80% of the weight loss of the 12 mg max dose with roughly half the dysesthesia risk.<\/p>\n

12 mg (Week 13+): Maximum Dose<\/h3>\n

The 12 mg weekly dose produced the landmark results that made retatrutide a headline drug. In TRIUMPH-4, the 68-week results showed 28.7% mean body weight reduction. However, 20.9% of participants at this dose developed dysesthesia \u2014 abnormal skin sensations such as tingling or burning \u2014 compared to 8.8% at 9 mg and 0.7% on placebo. Most dysesthesia cases were mild and did not cause discontinuation, but one in five patients experienced it. That is not nothing.<\/p>\n

The discontinuation rate due to side effects at 12 mg was approximately 6-7%, comparable to tirzepatide and lower than some semaglutide trials.<\/p>\n

The Case for 9 mg Maintenance Over 12 mg<\/h2>\n

TRIUMPH-4 tested a 9 mg maintenance dose alongside the 12 mg protocol. The results make a strong argument for staying lower:<\/p>\n